{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:16:22Z","timestamp":1784337382264,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Vaccination against pneumococcus reduces the risk of infective events, hospitalisation, and death in individual with inflammatory arthritis, particularly in those on immunomodulating therapy who are at risk of worse outcomes from pneumococcal disease. The objective of this study was to investigate the serological protection following vaccination against pneumococcal serovars over time. Methods: This was a single centre, retrospective cohort study of individuals with rheumatoid arthritis, psoriatic arthritis, or axial spondylarthritis who had previously received the PPSV23 polysaccharide pneumococcal vaccine (Pneumovax). Data were retrieved between January 2021 to August 2023. Dates of previous pneumococcal vaccination were identified using linked primary care records. Serum serotype levels were collected. The primary outcome was serological response defined as a titre \u22650.35 mcg\/mL in at least five from a total of 12 evaluated pneumococcal serovars, examined using a Luminex platform. Multivariate logistic regression models adjusting for age, gender, ethnicity, co-morbidities, and the use of prednisolone, conventional synthetic and biological DMARDs were used to determine the odds of a sustained serological response according to time categorised into \u22645 years, 5\u201310 years, and \u226510 years since vaccination. Results: Serological response was measured in 296 individuals with inflammatory arthritis, with rheumatoid arthritis the most common diagnosis (74% of patients). The median time between pneumococcal vaccine administration and serological assessment was 6 years (interquartile range 2.4 to 9.9). A positive serological response to at least 5 serovars was present in 195\/296 (66%) of patients. Time since vaccination did not significantly associate with serological protection compared with those vaccinated &lt;5 years, the adjusted ORs of vaccine response was 1.15 (95% CI 0.64 to 2.07) in those 5\u201310 years and 1.26 (95% CI: 0.64 to 2.48) in those vaccinated over 10 years ago. No individual variable from the multivariate model reached statistical significance as an independent predictor of vaccine response, although steroid use at the time of vaccine had a consistent detrimental impact on serological immunity. Conclusions: We demonstrated that antibody titres following vaccination against pneumococcal serovars do not appear to wane over time. It appears more critical to focus on maximising the initial vaccine response, which is known to be diminished in this patient population.<\/jats:p>","DOI":"10.3390\/vaccines12010069","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:50:48Z","timestamp":1704873048000},"page":"69","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre Cohort"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-6528","authenticated-orcid":false,"given":"Deepak","family":"Nagra","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Russell","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Adas","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Subesinghe","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rutherford","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Alveyn","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wincup","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Mahto","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-215X","authenticated-orcid":false,"given":"Ioasaf","family":"Karafotias","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cope","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis","volume":"24","author":"Spijker","year":"2018","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11865","DOI":"10.1038\/s41598-021-91234-y","article-title":"Prognostic factors for mortality in invasive pneumococcal disease in adult: A system review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(20)30880-X","article-title":"Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance","volume":"21","author":"Mackenzie","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1017\/S0950268819001559","article-title":"Pneumonia incidence trends in UK primary care from 2002 to 2017: Population-based cohort study","volume":"147","author":"Sun","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chen, Z., Cox, K.S., Tang, A., Roman, J., Fink, M., Kaufhold, R.M., Guan, L., Xie, A., Boddicker, M.A., and Mcguinness, D. (2018). Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3517-7"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Papadatou, I., Tzovara, I., and Licciardi, P.V. (2019). The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects. Vaccines, 7.","DOI":"10.3390\/vaccines7010013"},{"key":"ref_9","unstructured":"Agency UHS (2023, September 22). Pneumococcal: The Green Book, Chapter 25, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1178054\/Green_Book_Chapter_25_Pneumococcal_27_7_23.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.vaccine.2021.02.009","article-title":"A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness","volume":"39","author":"Constantinou","year":"2021","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nagra, D., Bechman, K., Adas, M., Yang, Z., Alveyn, E., Subesinghe, S., Rutherford, A., Allen, V., Patel, S., and Russell, M.D. (2023). A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis. Vaccines, 11.","DOI":"10.3390\/vaccines11111680"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41541-023-00756-1","article-title":"Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2","volume":"8","author":"Jacobsen","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged \u2265 18 Years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1016\/j.vaccine.2022.09.069","article-title":"Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation","volume":"40","author":"Wolf","year":"2022","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C.R., Martins, K., and Jayashankar, L. (2021). Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv.","DOI":"10.1101\/2021.08.09.21261290"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1038\/s41467-023-40195-z","article-title":"Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology","volume":"14","author":"Huiberts","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/CDLI.10.4.514-519.2003","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2018.08.002","article-title":"Measuring immune responses to pneumococcal vaccines","volume":"461","author":"LaFon","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1503\/cmaj.110977","article-title":"Missing covariate data in clinical research: When and when not to use the missing-indicator method for analysis","volume":"184","author":"Groenwold","year":"2012","journal-title":"CMAJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0924-8579(99)00167-3","article-title":"Antibody response of pneumococcal vaccine: Need for booster dosing?","volume":"14","author":"Mufson","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000441-198705000-00001","article-title":"Pneumococcal antibody levels one decade after immunization of healthy adults","volume":"293","author":"Mufson","year":"1987","journal-title":"Am. J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jcp.2006.041210","article-title":"Anti-pneumococcal antibody titre measurement: What useful information does it yield?","volume":"60","author":"Balmer","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S1473-3099(22)00438-8","article-title":"Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: An observational, population-level, serosurveillance study","volume":"22","author":"Swarthout","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Van Westen, E., Knol, M.J., Wijmenga-Monsuur, A.J., Tcherniaeva, I., Schouls, L.M., Sanders, E.A., Van Els, C.A., Berbers, G.A., and Rots, N.Y. (2018). Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine. Vaccines, 6.","DOI":"10.3390\/vaccines6040082"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Garcia Garrido, H.M., Vollaard, A., D\u2019haens, G.R., Spuls, P.I., Bemelman, F.J., Tanck, M.W., de Bree, G.J., Meek, B., Grobusch, M.P., and Goorhuis, A. (2022). Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. Vaccines, 10.","DOI":"10.3390\/vaccines10050795"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e202201381","DOI":"10.26508\/lsa.202201381","article-title":"mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients","volume":"5","author":"Azzolini","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"880784","DOI":"10.3389\/fimmu.2022.880784","article-title":"Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals","volume":"13","author":"Paramithiotis","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"727850","DOI":"10.3389\/fimmu.2021.727850","article-title":"Humoral and Cellular Response Following Vaccination with the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies","volume":"12","author":"Amodio","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/RHU.0000000000000877","article-title":"Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and\/or Biologics Therapy","volume":"25","author":"Intongkam","year":"2019","journal-title":"J. Clin. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1081-1206(10)60572-8","article-title":"Assessment and clinical interpretation of polysaccharide antibody responses","volume":"99","author":"Paris","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/0004563213500241","article-title":"Making sense of serotype-specific pneumococcal antibody measurements","volume":"50","author":"Beck","year":"2013","journal-title":"Ann. Clin. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00127-18","DOI":"10.1128\/mSphere.00127-18","article-title":"Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides","volume":"3","author":"Tan","year":"2018","journal-title":"mSphere"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/CVI.00735-14","article-title":"Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function","volume":"22","author":"Daly","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_35","unstructured":"Agency, E.M. (2023, December 01). Prevenar 13 Suspension for Injection Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prevenar-13-epar-product-information_en.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System","volume":"10","author":"Strehl","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/1\/69\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:43:38Z","timestamp":1760103818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/1\/69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["vaccines12010069"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12010069","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]}}}